Pfizer (NYSE:PFE) reported better-than-expected results for the second quarter. The pharmaceutical giant achieved a profit per share of 67 cents on revenue amounting to $12.7 billion, surpassing the Street estimate of 57 cents per share on revenue of $12.08 billion.
CEO Albert Bourla expressed optimism about the future, stating that they anticipate further progress in the second half of 2023. This progress will be driven by their commercial execution, scientific innovation, and unwavering commitment to providing breakthroughs for patients.
For the full year, Pfizer expects earnings per share to be $3.35 with revenue reaching $68.5 billion. This forecast exceeded analysts’ expectations, as they were looking for earnings per share of $3.01 on revenue of $61 billion.